Chargement en cours...
Interferon Beta-1a (AVONEX(®)) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study
The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment gaps or switches are common. The Avonex as Treatmen...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4519899/ https://ncbi.nlm.nih.gov/pubmed/26154767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160715271 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|